Article Text

PDF
SAT0374 The euromyositis registry: an international description of myositis
  1. JB Lilleker1,
  2. J Vencovsky2,
  3. G Wang3,
  4. LR Wedderburn4,
  5. LP Diederichsen5,
  6. J Schmidt6,
  7. P Jordan7,
  8. O Benveniste8,
  9. MG Danieli9,
  10. K Dankό10,
  11. NTP Thuy11,
  12. M Vazquez-Del Mercado12,
  13. Ø Molberg13,
  14. B De Paepe14,
  15. J De Bleecker15,
  16. B Maurer16,
  17. N Pipitone17,
  18. N McHugh18,19,
  19. Z Betteridge18,19,
  20. P New20,
  21. RG Cooper20,
  22. WE Ollier1,
  23. JA Lamb1,
  24. NS Krogh21,
  25. IE Lundberg22,
  26. H Chinoy23,
  27. on behalf of UKMYONET and all contributors to the EuroMyositis Registry
  1. 1Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, United Kingdom
  2. 2Institute of Rheumatology, Charles University, Prague, Czech Republic
  3. 3Rheumatology, China-Japan Friendship Hospital, Beijing, China
  4. 4UCL GOS Institute of Child Health, London, United Kingdom
  5. 5Rheumatology, Odense University Hospital, Odense, Denmark
  6. 6Neurology, University Medical Center, Göttingen, Germany
  7. 7Myositis UK, Southampton, United Kingdom
  8. 8Médecine Interne et Immunologie Clinique, Hôpital Pitié-Salpêtrière, Paris, France
  9. 9Scienze Cliniche e Molecolari, Università Politecnica delle Marche & Ospedali Riuniti, Ancona, Italy
  10. 10Immunology, University of Debrecen, Debrecen, Hungary
  11. 11Rheumatology, Bach Mai Hospital, Hanoi, Viet Nam
  12. 12Medicina Interna, Hospital Civil Dr. Juan I. Menchaca, Guadalajara, Mexico
  13. 13Rheumatology, Oslo University Hospital, Oslo, Norway
  14. 14Neurology
  15. 15Ghent University Hospital, Ghent, Belgium
  16. 16Rheumatology, University Hospital Zurich, Zurich, Switzerland
  17. 17Rheumatology, Arcispedale S. Maria Nuova, Reggio Emilia, Italy
  18. 18Royal National Hospital for Rheumatic Diseases
  19. 19Pharmacy and Pharmacology, University of Bath, Bath
  20. 20Rheumatology, Salford Royal NHS Foundation Trust, Salford, United Kingdom
  21. 21ZiteLab ApS, Frederiksberg, Denmark
  22. 22Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden
  23. 23NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom

Abstract

Background The idiopathic inflammatory myopathies (IIM) represent a rare and heterogeneous group of multisystem autoimmune diseases. The rarity of IIM has hampered research efforts, resulting in remarkably limited therapeutic evidence. The EuroMyositis Registry was created to pool resources and expertise across the international IIM research community.

Objectives To describe the phenotypic characteristics of different IIM subtypes. Associations with malignancy, interstitial lung disease (ILD), cardiac involvement and dysphagia were assessed.

Methods Pooled data from the EuroMyositis Registry (from Belgium, China, Czech Republic, Hungary, Italy, Mexico, Norway, Sweden, Switzerland, UK, Vietnam) were obtained. Associations were assessed using logistic regression and multinomial logistic regression with polymyositis (PM) as the reference group.

Results Data regarding 3,196 patients were analysed. The UK was the largest contributor (n=1,307). The most common diagnoses were dermatomyositis (34%), PM (32%) and connective tissue disease (CTD)-overlap myositis (15%). In those with anti-synthetase syndrome (7%), 85% had muscle weakness, 86% ILD and 58% arthritis. Overall, 43% had a myositis specific antibody, most commonly anti-Jo1 autoantibodies (20%). Glucocorticoid usage was noted in 98%. Most commonly used disease modifying agents were methotrexate (71%) and azathioprine (50%).

Malignancy occurred in 9% and was associated with a diagnosis of dermatomyositis (Relative Risk Ratio [RRR] 1.68, 95% CI 1.09–2.56, p=0.018). Cardiac involvement occurred in 9%, most commonly in those with CTD-overlap myositis (13%), and was associated with a higher Health Assessment Questionnaire disability index (1 versus 0.75, OR 1.40, 95% CI 1.03–1.91, p=0.031). Dysphagia occurred in 39% and was associated with a diagnosis of CTD-overlap myositis (RRR 2.25, 95% CI 1.61–3.15, p<0.001).

Conclusions This large international cohort demonstrates the heterogeneity of IIM and the burden of associated malignancy, ILD, cardiac and gastrointestinal involvement. The EuroMyositis Registry facilitates international collaborative research outputs, underlining the benefits of harmonised data collection methodology between centres.

Acknowledgements This work was supported by researchers at the National Institute for Health Research (NIHR) Biomedical Research Unit. The views expressed are those of the authors and not necessarily those of the UK National Health Service, the NIHR or the UK Department of Health

Disclosure of Interest J. Lilleker: None declared, J. Vencovsky: None declared, G. Wang: None declared, L. Wedderburn Grant/research support from: The UK JDM Cohort and Biomarker study is supported by grants from the NIHR and Myositis UK, L. Diederichsen: None declared, J. Schmidt: None declared, P. Jordan: None declared, O. Benveniste: None declared, M. G. Danieli: None declared, K. Dankό: None declared, N. T. P. Thuy: None declared, M. Vazquez-Del Mercado: None declared, Ø. Molberg: None declared, B. De Paepe: None declared, J. De Bleecker: None declared, B. Maurer Grant/research support from: AbbVie, Protagen, EMDO, Novartis, Roche, Actelion, N. Pipitone Speakers bureau: GRAPPA Workshop, Alfa-Wassermann, N. McHugh: None declared, Z. Betteridge: None declared, P. New: None declared, R. Cooper: None declared, W. Ollier: None declared, J. Lamb Grant/research support from: MedImmune, N. S. Krogh: None declared, I. Lundberg Grant/research support from: Astra-Zeneca, Bristol-Myers Squibb, Consultant for: Bristol-Myers Squibb, Idera, H. Chinoy Grant/research support from: MedImmune, Novartis

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.